1 / 26

Unused Medications

Unused Medications. Where are we now?. Prepared for: U.S. Drug Enforcement Administration By: Dr. Jeanie Jaramillo and Dr. Stevan Gressitt July 19, 2011 . Disclosures. Poison Center Incentive Grant funded by HRSA No other potential conflicts of interest. Context. Acknowledgement.

darrion
Télécharger la présentation

Unused Medications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Unused Medications Where are we now? Prepared for: U.S. Drug Enforcement Administration By: Dr. Jeanie Jaramillo and Dr. StevanGressitt July 19, 2011

  2. Disclosures • Poison Center Incentive Grant funded by HRSA • No other potential conflicts of interest

  3. Context

  4. Acknowledgement • This presentation includes information collected and compiled by the Pharmaceutical Collection Monitoring Group • through use of the • Pharmaceutical Collection • Monitoring System™

  5. Purpose for Visit • There’s an elephant in the room • Not that unused medications are a problem • Now common knowledge: • Meds as a source of poisonings • Source of abuse (and diversion) • Source of misuse • Source of environmental contamination • Finding a solution • Band aid approach is no longer enough • Take back events are a band aid approach

  6. Root Cause Analysis is Needed • Define the problem factually • Gather data and evidence • Ask “why” and identify causes • Identify corrective actions that will prevent recurrence • Implement actions • Observe effect

  7. Purpose for Visit • We’ve hit a brick wall at step #2 (gather data and evidence) • We need the help of the DEA • Outline • Discuss successful collection events • Data utility • Share results • Request support

  8. Data Collection • Numerous take backs across country • Several high-quality data sets • Gressitt • Mireles • Gottlieb • Jaramillo • All data sets collected different data points • No consistency • Merging of data difficult if not impossible

  9. Pharmaceutical Collection Monitoring System™ (PCMS) • Web-based recording and reporting tool • Provides for collection of consistent data across multiple sites • Accessible by users anywhere that internet service is available

  10. A Case Report: Car #188 • Amarillo, Texas • Population: ~180,000 • Community Medication Take Back Event • Drive through • Collaborative effort with Amarillo Police Department

  11. Car #188

  12. Car #188 • 2 large boxes • Medications from deceased parents and cat • Speculatively parents both suffered from chronic, terminal diseases • Reporting today only the controlled substances from this vehicle

  13. Controlled Substances from Car #188 Values obtained from NDIC reports. Indicate estimates.

  14. Car #188 • Rare occurrence or more common than we think? • No data • Of what use would the data be? Would it really help anything?

  15. What data do we have?

  16. April 30th DEA Take Back Day • Eight organizations • 11 sites • Conducted events and logged data • Goal: data from at least first 50 participants • Result: data from items of 411 participants was collected • 3,800 line items logged

  17. April 30th DEA Take Back Day

  18. Most Commonly Collected Controls Acetaminophen with hydrocodone 22.7% Acetaminophen with propoxyphene 21.3% Benzodiazepines 11.3%

  19. By Schedule • See handout report • C II • C III • C IV • C V

  20. Medication Utilization/ Wastage • Controlled substances collected/documented • On average, 67% of dispensed controls were brought to take back events for disposal • 67% = wasted • Overprescribed? • Over-marketed? 60% 20% 10% 18% *total >100% as some participants selected >1 answer Percentages indicate what event participants would do with meds if event was unavailable.

  21. Why come to the DEA • Data has utility; greatly needed • Lost participation of sites due to lack of DEA support • Current directives • No questions • No counts • No handling of meds

  22. Why come to the DEA? • Need DEA to be part of the solution • Funding? • Letter of support? • Letter of understanding?

  23. DEA PCMS Academia Local Law Enforcement. Community Partners.

  24. Contact Information • Jeanie Jaramillo • jeanie.jaramillo@ttuhsc.edu • (806) 354-1611 • StevanGressitt • gressitt@gmail.com • (207)441-0291

More Related